Lucid Diagnostics (LUCD) AGM 2026 summary

Opening remarks and agenda

• The meeting was called to order by the Chairman and CEO, with key executives, auditors, and counsel present.

• Housekeeping items included instructions for voting, submitting questions, and accessing the certified list of stockholders via the webcast platform.

Board and executive committee updates

• Three Class B directors—James L. Cox, MD, John R. Palumbo, and Ronald M. Sparks—were nominated for re-election to serve until the third succeeding annual meeting.

Shareholder proposals

• Proposal to amend the certificate of incorporation to increase authorized common stock from 300 million to 400 million shares was presented.

• Proposal to ratify the appointment of CBIZ CPAs as independent auditors for the year ending December 31, 2026, was considered.